Braidwell LP Takes $532,000 Position in Cyclerion Therapeutics, Inc. $CYCN

Braidwell LP acquired a new stake in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 156,890 shares of the company’s stock, valued at approximately $532,000. Braidwell LP owned about 3.35% of Cyclerion Therapeutics at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Two Sigma Investments LP acquired a new position in Cyclerion Therapeutics during the third quarter worth $31,000. BlackRock Inc. acquired a new stake in shares of Cyclerion Therapeutics in the second quarter worth about $57,000. Finally, ADAR1 Capital Management LLC bought a new stake in shares of Cyclerion Therapeutics during the 2nd quarter worth about $1,013,000. 75.62% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Cyclerion Therapeutics in a report on Friday, July 24th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Cyclerion Therapeutics Trading Up 8.4%

Shares of CYCN stock opened at $4.52 on Thursday. The firm has a market capitalization of $21.15 million, a P/E ratio of -2.72 and a beta of 1.75. Cyclerion Therapeutics, Inc. has a 1 year low of $1.03 and a 1 year high of $8.48. The firm’s fifty day simple moving average is $3.70 and its 200 day simple moving average is $3.00.

Cyclerion Therapeutics shares are going to reverse split on Wednesday, September 9th. The 1-7 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Tuesday, September 8th.

Cyclerion Therapeutics (NASDAQ:CYCN) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($7.10) by $6.69. Cyclerion Therapeutics had a negative net margin of 170.11% and a negative return on equity of 87.96%. Equities research analysts anticipate that Cyclerion Therapeutics, Inc. will post -1.2 EPS for the current fiscal year.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.